Quanterix Q2 revenue rises 34% but cuts 2026 outlook
QTRX•Q2 revenue rises, loss narrows
Quanterix said second-quarter revenue rose 34% year over year amid execution challenges and market softness.
Adjusted EBITDA loss for the quarter narrowed to $10.0 million from $13.7 million in the prior year.
Drivers behind the lower outlook
The company said revenue fell short of expectations due to execution issues and continued market softness.
Quanterix also said it reorganized teams and added experienced leaders to address performance and accountability.
It reported progress in advancing clinical adoption of blood-based Alzheimer's testing, including new insurance coverage and clinical data.
Key quarterly figures and analyst view
| Metric | Actual |
|---|---|
| Q2 Product Revenue | $23.48 million |
| Q2 Net Loss | $48.93 million |
| Q2 Gross Profit | $12.67 million |
| Q2 Loss Per Basic Share | $1.04 |
| Q2 Operating Expenses | $62.11 million |
| Q2 Operating Income | -$49.43 million |
The current average analyst rating on the shares is hold, with 3 hold ratings and no strong buy, buy, or ratings.
